In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3- carboxamide, commonly known as CUMYL-4CN-BINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.